Alzamend Neuro, Inc. Faces Nasdaq Delisting Warning

Hey everyone, let's break down some recent news from Alzamend Neuro, Inc. in a way that makes sense, without all the fancy finance talk. Think of this as me explaining it to you over coffee.

---

1. What happened? (in plain English - the actual event)

Alzamend Neuro received a letter from Nasdaq. This letter warns the company does not meet a key Nasdaq financial rule. They need this rule to stay listed on the stock exchange.

Their "stockholders' equity" fell below Nasdaq's minimum. This is what the company owns after paying all its debts. It's essentially what's left for the owners. They reported about $2.2 million in equity by January 31, 2026. Nasdaq requires at least $2.5 million. This $300,000 shortfall triggered the warning.

Think of it like a student getting a warning about low grades. If they don't improve, they might get kicked out. It's a serious warning about their financial health.

2. When did it happen?

The company officially received the Nasdaq letter on March 20, 2026. This notice followed their Quarterly Report (Form 10-Q). That report covered the quarter ending January 31, 2026.

3. Why did it happen? (context and background)

To understand this, know how stock exchanges like Nasdaq work. They set rules for listed companies. These rules ensure financial stability and good reputation. This protects investors and keeps the market fair.

One rule (Nasdaq Listing Rule 5550(b)(1)) requires companies to keep at least $2.5 million in stockholders' equity. This shows a company's financial health. Low equity suggests they lack assets to cover debts. This signals financial trouble and long-term risk.

Alzamend's recent report (Form 10-Q) showed about $2.2 million in equity. This is below the $2.5 million minimum. Total losses from R&D expenses caused this drop. This is common for biotech companies like Alzamend Neuro. They invest heavily in drug development without much income. That's why Nasdaq sent the warning letter.

4. Why does this matter? (impact and significance)

Why does this matter? It's a big deal because:

• For the company: This is a serious challenge. If Alzamend can't fix this, Nasdaq could remove their stock. Removal means their stock moves to a less visible market. This is called the over-the-counter (OTC) market. Think OTCQB or Pink Sheets. OTC trading means fewer experts follow the stock. Big investors often avoid it. Buying and selling becomes harder and more costly. The stock's value usually drops a lot. This makes it harder for the company to raise money. They also struggle to attract new investors. Their reputation in biotech also suffers.
• For the stock: News like this typically makes investors nervous. It signals financial trouble and delisting risk. This can cause the stock price to drop and become very unstable. Delisting often causes a big drop in share value. Sometimes it's 50% or more. Fewer buyers exist, and risk increases. Big investors and index funds often avoid OTC stocks. This makes the stock less appealing.
• For investors (that's you!): If you own Alzamend stock, this is a significant risk factor. Delisting means your shares may be harder to sell. They might trade for much less. You could also see reduced liquidity. It questions the company's long-term survival. They must meet basic financial rules to stay on a major exchange.

5. Who is affected? (employees, customers, investors, etc.)

Everyone connected to Alzamend feels the impact:

• Investors (that's you!): You're directly affected by the increased risk to the stock's value and liquidity.
• Alzamend's management: They face big pressure now. They must quickly create a plan to regain compliance. The market will watch how they handle this challenge. This includes finding new money or cutting costs.
• Alzamend's employees: They are not immediately impacted. But financial instability creates uncertainty. This includes future layoffs and job security. Funding for clinical trials could also become risky.
• Potential partners or lenders: This warning makes it harder for Alzamend to find partners. It also makes getting important loans tough. Alzamend Neuro develops drugs for brain disorders. Their main drugs are AL001 and ALZ-1901 for Alzheimer's. These programs need steady, large funding. Financial instability puts trials, manufacturing, and approvals at risk.

6. What happens next? (immediate and future implications)

Okay, so what's on the horizon?

• Immediate: The company has 45 days from March 20, 2026. This means until May 4, 2026. They must submit a plan to Nasdaq. This plan explains how they will meet the $2.5 million equity rule. It must detail specific actions.
• Next Big Step: If Nasdaq accepts their plan, Alzamend may get 180 days. This period runs until September 16, 2026. They must then show they meet the rule. This time lets them act on their plan. Actions could include selling more stock to raise money. They might also turn debt into ownership. Or they could become profitable.
• Longer Term: What if Nasdaq rejects their plan? Or if they don't meet the rule in time? Nasdaq could then say the stock will be removed. Alzamend can appeal this to a Nasdaq panel. This stops the removal process temporarily. But there is no guarantee they will win the appeal.
• Company's Stance: Alzamend is reviewing its options. They plan to submit their plan on time. But they stated "there can be no assurance" their plan will be accepted. They also cannot guarantee regaining compliance in time. This means they might not succeed. This could lead to delisting.

7. What should investors/traders know? (practical takeaways)

Alright, for those of you trading or thinking about investing, here's the lowdown:

• This is serious negative news: This is not a good sign. A delisting warning flags a company's core financial health. It questions their ability to operate on a major stock exchange.
• Delisting is a major risk: If the stock is removed, it usually moves to the OTC market. This means less visibility and fewer big buyers. The stock price often drops a lot. OTC trading can also make selling shares harder and more costly. Expect much lower liquidity.
• Expect volatility: Biotech stocks are naturally unstable. Drug development is high-risk. This news can cause big, lasting price swings. Prices will likely go down. Investors react to financial risk and uncertainty.
• Focus on the plan: Watch for the company's detailed plan. See if Nasdaq accepts it. A vague plan, or one without clear financial steps, is a bad sign. If rejected, it's very negative. Look for specifics on how they will boost equity. This could mean selling more stock, changing debt, or cutting costs.
• Do your own homework: Don't just read headlines. Check their financial reports (like the 10-Q). Understand their full financial picture. Look at their cash burn, current debts, and funding needs. Learn why equity dropped. See their realistic recovery options.
• This isn't about drug development (yet): Alzamend is a biotech company. They focus on vital drug development. But this issue is about basic financial health, not drug progress. Financial trouble can hurt their ability to fund trials. It impacts AL001 and ALZ-1901. It also affects manufacturing, talent, and approvals. This indirectly risks their drug pipeline long-term.

In short: This is a serious challenge for Alzamend Neuro. It directly impacts their ability to stay on a major exchange. It also affects funding their core mission. Stay informed about their compliance efforts. Trade wisely, understanding the significant risks.